Hydrogen-Filled Palladium Nanosheets, Activated by Light and Tracked by Sound, Erase Plaques and Restore Memory in Alzheimer’s Mice
Scientists in China have built a hydrogen-powered nanoscale weapon against Alzheimer’s disease — and in mice, it works well enough to make diseased brains behave like healthy ones. In a study published in BMC Neuroscience, researchers at Shanxi Medical University and its affiliated hospitals report that ultra-small palladium hydride (PdH) nanosheets, injected intravenously and then activated by an 808-nanometer near-infrared laser, cleared amyloid-β plaques, quenched the hydroxyl radicals that drive neuroinflammation, and restored near-normal performance on standard memory tests in Alzheimer’s model mice. What makes the platform unusual is that it is simultaneously a drug, a heater, and an imaging agent: each flake of palladium hydride stores therapeutic hydrogen inside its own crystal lattice, converts near-infrared light into precisely tuned heat, and lights up under photoacoustic imaging, allowing researchers to track its journey into the brain in real time. The 37-nanometer sheets crossed the blood-brain barrier, released their cargo on demand, and, in combination with light, brought the escape latency of treated animals in the Morris water maze down to levels statistically comparable with wild-type controls.
The scale of the problem the team is attacking is enormous. Alzheimer’s disease is the most common neurodegenerative disorder in the world, and as populations age, its incidence climbs every year; by 2050, the number of people living with dementia is projected to exceed 150 million. Despite decades of effort, no drug has been found that effectively reverses the disease, largely because its pathogenesis is complex and incompletely understood and its onset unfolds over many years. The pathological picture is dominated by the abnormal accumulation of amyloid-β (Aβ42), which triggers a cascade of further damage: the aggregates provoke the overproduction of reactive oxygen species (ROS), and the resulting oxidative stress is tightly entangled with neuroinflammation, synaptic dysfunction, and progressive memory loss. Because these processes feed one another, therapies that attack only a single target have struggled. Earlier nanomaterials, including protein-capped cadmium sulfide nanoparticles and a dipeptide-modified gold nanocluster that dissolved mature amyloid fibrils, showed that inorganic agents can act on protein aggregates, but many suffered from modest inhibitory efficiency and limited dissociation ability.
Hydrogen has long been an intriguing candidate for exactly this kind of multi-target problem. The biological effects of molecular hydrogen are attributed largely to its ability to selectively scavenge highly reactive oxygen species — above all the hydroxyl radical (∙OH) — without interfering with the physiologically important ROS that cells use for signaling. Its exceptional biosafety profile has been widely confirmed, and it has been explored as a treatment for numerous inflammatory conditions. The catch is delivery. Hydrogen is poorly soluble in water and diffuses rapidly, so conventional administration routes — inhaling hydrogen gas or drinking hydrogen-rich water — cannot achieve meaningful accumulation at inflammatory sites inside the brain. Worse, any molecule hoping to reach those sites must first negotiate the blood-brain barrier, the tightly sealed endothelial boundary that restricts the entry of most drugs. The authors argue that achieving sustained, in-situ release of hydrogen at the site of neuroinflammation is therefore the crucial step for turning hydrogen therapy from a promising idea into a practical treatment for Alzheimer’s disease.
The new study’s answer is to make palladium do the work. Palladium is famous among chemists for its appetite for hydrogen: hydrogen atoms can slip into the interstitial sites of its crystal lattice, giving the metal one of the highest hydrogen storage capacities of any element, and it is highly active in catalytic hydrogenation, especially at the nanoscale. The researchers first synthesized uniform palladium nanosheets by dissolving palladium(II) acetylacetone with poly(vinylpyrrolidone) and sodium bromide in a dimethylformamide–water mixture under a carbon monoxide atmosphere at 80 °C. They then bubbled hydrogen gas through the nanoparticle solution for 15 minutes, loading the sheets to form palladium hydride. Transmission electron microscopy revealed hexagonal nanosheets roughly 37 nanometers in diameter — comfortably below the 100-nanometer threshold at which inorganic nanoparticles can efficiently penetrate a wide range of tissues, including the blood-brain barrier — with good dispersion that favors storing, transferring, and releasing hydrogen. X-ray diffraction supplied the chemical proof: compared with metallic palladium, the PdH diffraction peaks shifted slightly toward smaller angles, which, according to Bragg’s law, reflects expansion of the crystal lattice as hydrogen atoms squeeze into the interstitial sites.
The same sheets turn out to be excellent light absorbers. When aqueous PdH solutions at different concentrations were irradiated with an 808-nanometer laser at 1 watt per square centimeter for five minutes — temperature changes tracked with an infrared thermal camera — the solutions heated steeply with both time and concentration, and the material showed no obvious attenuation across three repeated heating-and-cooling cycles, a sign of excellent photothermal stability. From the fitted cooling curve, the team calculated a photothermal conversion efficiency of 38.50 percent, a competitive figure for a photothermal agent. Ultraviolet-visible-near-infrared spectroscopy showed broad absorption across the 500-to-800-nanometer range, the typical signature of palladium nanostructures, with strong absorption extending into the near-infrared. That combination of high conversion efficiency and good biocompatibility positions PdH simultaneously as a photothermal therapy agent and a photoacoustic imaging agent — the same optical property that lets the sheets heat up enough to release hydrogen and disrupt amyloid aggregates also lets them generate the acoustic waves used to visualize them inside living tissue.
Perhaps the most elegant trick is how the hydrogen gets out. Normally, detecting hydrogen in solution requires platinum nanoparticles as a catalyst; methylene blue, a redox probe, will only register hydrogen’s reducing power with platinum’s help. The PdH sheets dispense with that requirement because they act as a platinum-like autocatalyst themselves, assisting the very hydrogenation reaction that releases their own stored hydrogen. In the methylene blue assay, absorbance plummeted rapidly in the presence of PdH, while pure palladium nanoparticles left the dye essentially untouched over the same reaction period — confirming that palladium alone is not enough and that the hydrogen-loaded hydride form is what actively carries and releases hydrogen. Laser irradiation made things better still: heating the sheets under the 808-nanometer laser further enhanced their reducing power. Complementary radical-scavenging tests reinforced the antioxidant story. In the ABTS assay, the solution progressively decolorized as PdH neutralized ABTS radical cations, with absorbance at 736 nanometers falling in a concentration-dependent manner, and the DPPH assay showed the characteristic purple-to-yellow transition as radicals were quenched at 520 nanometers.
All of this activity is choreographed by imaging. Injected through the tail vein, the nanosheets generated photoacoustic signals in both the first and second near-infrared windows, with the NIR-II window offering more precise localization within the brain and strong guidance for therapy. Paired with second near-infrared fluorescence imaging using an indocyanine-green-labeled formulation, PdH-ICG, the researchers watched fluorescence develop in the brain within two hours of intravenous injection, demonstrating that the sheets readily cross the blood-brain barrier and can be used stably at their target. The authors emphasize that this is where the small size matters most: the barrier is the body’s main obstacle to treating brain disease, and inorganic nanoparticles below roughly 100 nanometers can penetrate a wide range of tissues far more easily than larger carriers. Real-time photoacoustic monitoring means the therapeutic laser is never fired blindly — the operator can first confirm that the agent has accumulated at the lesion, localize the treatment precisely, and use the same signal to evaluate the outcome.
The decisive test came in a mouse model of Alzheimer’s disease. The team injected aggregated amyloid-β 25–35 peptide — aged for seven days at 37 °C to promote fibrillization — into the right lateral ventricle of Balb/c mice via stereotaxic surgery, then split the animals into four groups: healthy wild-type controls given saline, untreated Alzheimer’s mice, mice given PdH alone, and mice given PdH followed by laser. Treated animals received intravenous PdH at 5 milligrams per kilogram every three days for four weeks; the combination group also received 808-nanometer irradiation at 1 watt per square centimeter on the skull surface for five minutes after each injection to trigger on-demand hydrogen release. In the Morris water maze — a 90-centimeter circular pool filled with water held at 24 ± 1 °C, with a 9-centimeter platform hidden one centimeter beneath the surface — all groups learned across five days of training, but the Alzheimer’s mice consistently took far longer to find the platform, and the gap with healthy controls widened as training progressed. PdH alone shortened escape latency. Most strikingly, the PdH-plus-laser group performed at a level comparable to the wild-type animals, which the authors describe as a near-complete restoration of spatial learning. In the day-six probe trial, Alzheimer’s mice swam in aimless, wall-hugging patterns, while the laser-treated mice concentrated their search in the quadrant where the platform had once been, indicating precise spatial memory.
The Y-maze test told the same story: spontaneous alternation — the tendency of a healthy rodent to explore a new arm of the maze rather than revisit the one it just left — was significantly impaired in the Alzheimer’s group compared with wild-type mice, partially rescued by PdH treatment alone, and more robustly reversed by PdH plus laser, bringing alternation percentages back to a level akin to that of normal animals. The authors trace the behavioral rescue to a set of mutually reinforcing mechanisms. The nanosheets enable sustained and light-triggered release of hydrogen, which directly scavenges cytotoxic hydroxyl radicals, easing the oxidative stress and downstream neuroinflammation that drive synaptic dysfunction and memory loss. The photothermal effect does double duty: it accelerates hydrogen release, may contribute directly to the suppression of amyloid-β aggregation, and transiently enhances blood-brain barrier permeability to improve delivery. Photoacoustic guidance keeps the entire sequence precise, ensuring the agents reach their target sites before any therapeutic light is applied.
The researchers are careful about what the results do and do not show. The model relies on injecting pre-aggregated amyloid peptide into the ventricles rather than the slow, whole-body progression of human disease, the behavioral cohorts were small, and moving the platform toward the clinic will require answers to questions the mouse study cannot address: how much near-infrared light can safely reach deep structures through a thicker human skull, how palladium behaves in the brain over months and years, and whether the transient barrier opening carries risks. Even so, the team argues that the demonstration addresses two of the field’s most stubborn challenges at once — getting an active therapy across the blood-brain barrier and intervening against multiple pathological hallmarks simultaneously — and that the approach may open a new window for treating Alzheimer’s disease. The work, funded by science and technology programs of Shanxi Province, suggests that the same logic of image-guided, hydrogen-delivering, light-activated nanomedicine could plausibly extend to other neurodegenerative conditions marked by protein aggregation and oxidative damage.
Subject of Research: Dual-functional palladium hydride (PdH) nanosheets enabling photoacoustic imaging-guided hydrogen delivery and photothermal therapy for amyloid-β clearance and antioxidant treatment of Alzheimer’s disease
Subject of Research: Medicine
Article Title: Precise Aβ clearance and antioxidant therapy in Alzheimer’s disease via photoacoustic imaging-guided palladium hydride nanosheet-mediated photothermal treatment
Article References: Yu, L., Zhao, M., Zhang, W., Lv, Z., Zhao, K., Li, H., Qi, Y., Peng, X., Zheng, Z., & Zhang, W. (2026). Precise Aβ clearance and antioxidant therapy in Alzheimer’s disease via photoacoustic imaging-guided palladium hydride nanosheet-mediated photothermal treatment. BMC Neuroscience, 27(1), Article 8. https://doi.org/10.1186/s12868-025-00994-0
Image Credits: AI Generated
DOI: 10.1186/s12868-025-00994-0
Keywords: Alzheimer’s disease, Palladium hydride nanosheets, Photothermal treatment, Synergistic treatment strategy, Hydrogen therapy, Amyloid-β, Blood-brain barrier, Photoacoustic imaging, Oxidative stress, Neuroinflammation, Nanomedicine
Cite Scienmag News
APA MLA Chicago
Clara W. (August 29, 2026). Photoacoustic-guided palladium nanosheets clear Alzheimer’s amyloid plaques and ease oxidative stress. Scienmag. https://scienmag.com/photoacoustic-guided-palladium-nanosheets-clear-alzheimers-amyloid-plaques-and-ease-oxidative-stress/
Clara W. “Photoacoustic-guided palladium nanosheets clear Alzheimer’s amyloid plaques and ease oxidative stress.” Scienmag, 29 August 2026, https://scienmag.com/photoacoustic-guided-palladium-nanosheets-clear-alzheimers-amyloid-plaques-and-ease-oxidative-stress/. Accessed 29 August 2026.
Clara W. “Photoacoustic-guided palladium nanosheets clear Alzheimer’s amyloid plaques and ease oxidative stress.” Scienmag. August 29, 2026. https://scienmag.com/photoacoustic-guided-palladium-nanosheets-clear-alzheimers-amyloid-plaques-and-ease-oxidative-stress/
Copy citation Download RIS
Tags: Alzheimer’s amyloid plaque clearanceAlzheimer’s disease treatmentamyloid-β plaque clearanceblood-brain barrier crossingblood-brain barrier crossing by nanosheetshydrogen-activated nanomaterialshydrogen-filled palladium hydride nanomaterialslight-activated therapeutic nanoplatformsmemory restoration in Alzheimer’s disease micememory restoration in Alzheimer’s modelsmultifunctional nanoplatformsnanomaterials for neuroinflammation mitigationnanoscale drug delivery systemsnanotechnology for neurodegenerative diseasesnear-infrared laser activationnear-infrared laser therapyneuroinflammation reductionoxidative stress mitigationoxidative stress reduction in Alzheimer’sphotoacoustic imaging in brain therapyphotoacoustic imaging in neurosciencePhotoacoustic-guided palladium nanosheets
